A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
This study is currently recruiting participants.
Verified March 2017 by Ian F. Pollack, M.D., University of Pittsburgh
University of Pittsburgh
First Posted: May 25, 2010
Last Update Posted: March 30, 2017
Ellie Kavalieros Fund
Translational Brain Tumor Research Fund
Information provided by (Responsible Party):
Ian F. Pollack, M.D., University of Pittsburgh
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||February 2020|
|Estimated Primary Completion Date:||February 2019 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 1;32(19):2050-8. doi: 10.1200/JCO.2013.54.0526. Epub 2014 Jun 2.